Since 2009, when the CD3 and CD19 BsAb (a bispecific T cell engager, BiTE) blinatumomab was approved by the FDA for the treatment of Philadelphia chromosome-negative R/R B-ALL [180], increasing numbers of BsAbs have been developed. Here, CD19 is linked to acute lymphoblastic leukemia.